Positive News SentimentPositive NewsNASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $5.72 -0.20 (-3.38%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$6.42 +0.70 (+12.24%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Profound Medical Stock (NASDAQ:PROF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Profound Medical alerts:Sign Up Key Stats Today's Range$5.71▼$5.9750-Day Range$5.60▼$8.3652-Week Range$4.80▼$8.95Volume77,661 shsAverage Volume125,804 shsMarket Capitalization$208.97 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Profound Medical Corp. is a medical technology company focused on developing and commercializing incisionless therapies for prostate disease. The company’s principal product is the TULSA-PRO system, an MRI-guided, robotic platform designed to deliver precise transurethral ultrasound ablation of prostate tissue. The system combines real-time magnetic resonance imaging, automated treatment planning and temperature monitoring to help physicians target and destroy tissue while seeking to protect structures surrounding the prostate. TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia. The platform is intended to provide a minimally invasive alternative to certain surgical or radiation-based procedures. Profound Medical has obtained regulatory clearances and approvals for TULSA-PRO in the United States, Canada and other international markets, and the company markets the system through hospitals, clinics and physician networks in North America and selected markets internationally. Profound Medical is headquartered in Toronto, Canada. The company was founded to advance image-guided therapeutic technologies and has focused its commercial efforts on expanding adoption of TULSA-PRO and supporting physicians with clinical training and treatment services. Arun Menawat has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 51% of companies evaluated by MarketBeat, and ranked 508th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingProfound Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialProfound Medical has a consensus price target of $11.50, representing about 101.0% upside from its current price of $5.72.Amount of Analyst CoverageProfound Medical has only been the subject of 2 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($0.81) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.37% of the float of Profound Medical has been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 12.33, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently decreased by 3.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.82 News SentimentProfound Medical has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Profound Medical this week, compared to 2 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by Insiders1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROF Stock News HeadlinesFinancial Survey: Profound Medical (NASDAQ:PROF) versus Tenon Medical (NASDAQ:TNON)4 hours ago | americanbankingnews.comProfound Medical Stock And 2 Canadian AI Healthcare Stocks To WatchSeptember 6, 2026 | finance.yahoo.comA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold. Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program. With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district.September 30 at 1:00 AM | Wall Street Logic (Ad)Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceSeptember 3, 2026 | financialpost.comFProfound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth ConferenceSeptember 3, 2026 | globenewswire.comProfound Medical Appoints Richard Fabian PresidentSeptember 2, 2026 | marketscreener.comMProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentSeptember 1, 2026 | financialpost.comFProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentSeptember 1, 2026 | globenewswire.comSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.87 at the beginning of 2026. Since then, PROF stock has decreased by 27.3% and is now trading at $5.72. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The firm earned $2.48 million during the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative trailing twelve-month return on equity of 63.03% and a negative net margin of 171.57%. Read the conference call transcript. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings8/06/2026Today9/30/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, PROF's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees162Year Founded2008Price Target and Rating Average Price Target for Profound Medical$11.50 High Price Target$12.00 Low Price Target$11.00 Potential Upside/Downside+101.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.57 million Net Margins-171.57% Pretax Margin-170.37% Return on Equity-63.03% Return on Assets-51.24% Debt Debt-to-Equity RatioN/A Current Ratio6.46 Quick Ratio5.31 Sales & Book Value Annual Sales$19.09 million Price / Sales10.95 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book3.13Miscellaneous Outstanding Shares36,533,000Free Float35,978,000Market Cap$208.97 million OptionableOptionable Beta0.72 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PROF) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersThis Nasdaq Name Spent 25 Years Preparing for America's Next Big MoveA Nasdaq listed company has spent more than 25 years developing professional drone technology now central to W...i2i Marketing Group, LLC | SponsoredDr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Wants to Reprice America's Gold at Market ValueThe US government still values its gold reserves at 42 dollars an ounce, a price Congress set in 1973. Gold tr...Concord Gold Capital | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
